Convertible Notes (Details Narrative) - USD ($)		6 Months Ended			12 Months Ended
Convertible Notes (Details Narrative) - USD ($)	Apr. 04, 2018	Mar. 31, 2022	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2018	Jan. 14, 2021
Carrying value of convertible notes		$ 11,797	$ 7,834
Unamortized discount		$ 15,271	$ 19,233
Common Stock, Par Value		$ 0.001	$ 0.001
Accretion Expense		$ 729
Fair value of the derivative liability		10,133	$ 0
Proceeds from convertible debt		$ 30,000
Due date of note		January 18, 2023
Rate of interest on unpaid balance after default of note		10
Face value of convertible notes		$ 30,000
Convertible Note [Member]
Common Stock, Par Value	$ 0.0001
Beneficial conversion feature	$ 32,485
Due date of note	April 4, 2023
Rate of interest	12
Face value of convertible notes	$ 32,485
Amount Owed to Related Party	$ 32,485
Series A Convertile Notes [Member]
Accretion Expense				$ 1,670	$ 375	$ 3,112
Convertible notes				$ 1,853	$ 390	$ 3,175
Common stock, shares issued upon conversion of convertible shares				18,525,000	3,900,000	31,745,000
Series A Convertile Notes [Member] \| Family Member of President [Member]
Common stock, shares issued upon conversion of convertible shares						5,320,000
January 14, 2020 [Member] \| Unrelated party [Member]
Carrying value of convertible notes		$ 112,084	112,084
Description of conversion of convertible notes		The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal to lower of: 65% of the lowest trading price during the 20-trading day period prior to the issuance date; or (ii) 65% of the lowest trading price during the 20-trading day period prior to the conversion date.
Beneficial conversion feature		$ 76,330
Accretion Expense		3,963	1,744	$ 16,447
Convertible notes		78,000
Fair value of the derivative liability		447,469	264,481
Proceeds from convertible debt		$ 75,000
Due date of note		January 14, 2021
Rate of interest		12
Rate of interest on unpaid balance after default of note		15
Maximum intrinsic value of the embedded beneficial conversion feature		$ 74,500
Loss on change in fair value of derivative		1,830
Face value of convertible notes		78,000
Principal amount converted into common stock			$ 18,923
Common stock, shares issued upon conversion of convertible shares			2,600,000
Financing cost of convertible note		3,000
Conversion fees			$ 4,500
Principal default of convertible note							$ 53,007
January 22, 2020 [Member] \| Unrelated party [Member]
Carrying value of convertible notes		$ 78,750	78,750
Description of conversion of convertible notes		The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal to 65% of the lowest trading price during the 20-trading day period ending on the latest complete trading day prior to the conversion date.
Beneficial conversion feature		$ 75,179
Accretion Expense				$ 78,250
Convertible notes		78,750
Fair value of the derivative liability		359,055	$ 207,522
Proceeds from convertible debt		$ 69,000
Due date of note		January 22, 2021
Rate of interest		10
Rate of interest on unpaid balance after default of note		24
Maximum intrinsic value of the embedded beneficial conversion feature		$ 68,500
Loss on change in fair value of derivative		6,679
Face value of convertible notes		78,750
Directly paid to third party for financing		$ 9,750

Pharmagreen Biotech Inc. 10-Q